[go: up one dir, main page]

MX2022006069A - Metodo para tratar glomerulopatia c3. - Google Patents

Metodo para tratar glomerulopatia c3.

Info

Publication number
MX2022006069A
MX2022006069A MX2022006069A MX2022006069A MX2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A MX 2022006069 A MX2022006069 A MX 2022006069A
Authority
MX
Mexico
Prior art keywords
glomerulopathy
treating
human
susceptible
administering
Prior art date
Application number
MX2022006069A
Other languages
English (en)
Inventor
Petrus Bekker
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2022006069A publication Critical patent/MX2022006069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporcionan métodos para tratar un humano que padece de o es susceptible a glomerulopatía C3 que comprende administrar al humano una cantidad efectiva de un antagonista de C5aR.
MX2022006069A 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3. MX2022006069A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US201662397527P 2016-09-21 2016-09-21
PCT/US2017/013132 WO2017123716A1 (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Publications (1)

Publication Number Publication Date
MX2022006069A true MX2022006069A (es) 2023-01-12

Family

ID=59312069

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008624A MX2018008624A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.
MX2022006069A MX2022006069A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018008624A MX2018008624A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.

Country Status (18)

Country Link
US (3) US20170202821A1 (es)
EP (1) EP3402486B1 (es)
JP (4) JP7339733B2 (es)
KR (1) KR102767008B1 (es)
CN (1) CN108601790B (es)
AU (1) AU2017207359C1 (es)
BR (2) BR112018014222A2 (es)
CA (1) CA3010735C (es)
ES (1) ES3026359T3 (es)
IL (1) IL260539B (es)
MA (1) MA43872A (es)
MX (2) MX2018008624A (es)
NZ (1) NZ744083A (es)
RU (1) RU2742888C2 (es)
SG (1) SG11201805828YA (es)
TW (1) TWI791423B (es)
WO (1) WO2017123716A1 (es)
ZA (1) ZA201804513B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
BR112012033075B1 (pt) 2010-06-24 2021-06-01 Chemocentryx, Inc Composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto
NZ767823A (en) 2014-09-29 2023-05-26 Chemocentryx Inc Processes and intermediates in the preparation of c5ar antagonists
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
KR102767008B1 (ko) 2016-01-14 2025-02-11 케모센트릭스, 인크. C3 사구체병증을 치료하는 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
PL3985002T3 (pl) 2017-03-01 2025-09-15 Achillion Pharmaceuticals, Inc. Arylowe, heteroarylowe i heterocykliczne związki farmaceutyczne do leczenia zaburzeń medycznych
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
JP2020529227A (ja) * 2018-01-30 2020-10-08 プロクター アンド ギャンブル インターナショナル オペレーションズ エスエーＰｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｏｐｅｒａｔｉｏｎｓ Ｓａ 懸濁粒子を含む相安定で噴霧可能なフレッシュニング組成物
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
WO2020051538A1 (en) * 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
JP7342124B2 (ja) 2018-11-30 2023-09-11 ケモセントリックス，インコーポレイティド カプセル製剤
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
KR20220004024A (ko) 2019-03-22 2022-01-11 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 약제학적 조성물
MX2023001504A (es) * 2020-08-07 2023-04-27 Kira Pharmaceuticals Suzhou Ltd Compuestos como inhibidores del receptor del componente complemento 5a (c5ar).
MX2023007420A (es) * 2020-12-21 2023-06-29 Chemocentryx Inc Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
MXPA01002173A (es) 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
WO2002049993A2 (en) 2000-09-29 2002-06-27 Neurogen Corporation High affinity small molecule c5a receptor modulators
EP1278743A4 (en) 2000-05-05 2003-05-14 Smithkline Beecham Corp NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES
CA2418652C (en) 2000-08-10 2010-03-23 Mitsubishi Pharma Corporation Novel 3-substituted urea derivatives and medicinal use thereof
DK1318140T3 (da) 2000-09-14 2011-07-18 Mitsubishi Tanabe Pharma Corp Nye amidderivater og medicinsk anvendelse deraf
BRPI0211953B8 (pt) 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
CA2460121C (en) 2001-09-21 2010-11-02 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2479928A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004043223A2 (en) 2002-11-05 2004-05-27 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
EP1565452B1 (en) 2002-11-08 2012-04-04 Novartis International Pharmaceutical Ltd. 3-substituted-6-aryl pyridines as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101163693B (zh) 2005-02-18 2013-03-06 阿斯利康(瑞典)有限公司 抗菌哌啶衍生物
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
PT1951663T (pt) 2005-11-24 2016-10-03 Dompé Farm S P A ¿derivados (r)-arilalquilamino e composições farmacêuticas que os contêm
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2008053270A2 (en) * 2006-10-31 2008-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
AU2008272437A1 (en) 2007-06-29 2009-01-08 Torrent Pharmaceuticals Ltd. Novel substituted piperidones as HSP inducers
JP2011530596A (ja) 2008-08-11 2011-12-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ ｔＲＮＡ合成酵素の阻害のためのハロフジノン類似体およびそれらの使用
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
CA3035432A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
BR112012033075B1 (pt) 2010-06-24 2021-06-01 Chemocentryx, Inc Composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
US9452990B2 (en) * 2012-06-20 2016-09-27 Novartis Ag Complement pathway modulators and uses thereof
EP2994488B1 (en) 2013-05-08 2022-07-13 Novo Nordisk A/S Use of c5ar antagonists
NZ767823A (en) 2014-09-29 2023-05-26 Chemocentryx Inc Processes and intermediates in the preparation of c5ar antagonists
KR102767008B1 (ko) 2016-01-14 2025-02-11 케모센트릭스, 인크. C3 사구체병증을 치료하는 방법
MX384752B (es) 2016-04-04 2025-03-14 Chemocentryx Inc ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
MX2023007420A (es) 2020-12-21 2023-06-29 Chemocentryx Inc Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.

Also Published As

Publication number Publication date
JP7339733B2 (ja) 2023-09-06
US20190201388A1 (en) 2019-07-04
JP2019501935A (ja) 2019-01-24
SG11201805828YA (en) 2018-08-30
WO2017123716A1 (en) 2017-07-20
US11285138B2 (en) 2022-03-29
JP2024110998A (ja) 2024-08-16
CN108601790A (zh) 2018-09-28
ES3026359T3 (en) 2025-06-11
CA3010735A1 (en) 2017-07-20
US11779576B2 (en) 2023-10-10
MX2018008624A (es) 2018-12-10
US20220354837A1 (en) 2022-11-10
RU2018129378A (ru) 2020-02-14
EP3402486C0 (en) 2025-03-19
JP7788814B2 (ja) 2025-12-19
AU2017207359B2 (en) 2022-04-14
RU2018129378A3 (es) 2020-05-20
CA3010735C (en) 2023-06-13
NZ744083A (en) 2022-07-01
ZA201804513B (en) 2024-01-31
EP3402486A1 (en) 2018-11-21
JP2021183625A (ja) 2021-12-02
US20170202821A1 (en) 2017-07-20
BR112018014222A2 (pt) 2018-12-11
IL260539B (en) 2021-05-31
MA43872A (fr) 2021-05-19
KR102767008B1 (ko) 2025-02-11
EP3402486B1 (en) 2025-03-19
AU2017207359C1 (en) 2022-09-01
TWI791423B (zh) 2023-02-11
KR20180102642A (ko) 2018-09-17
JP2023126235A (ja) 2023-09-07
BR122024002810A2 (pt) 2024-03-12
AU2017207359A1 (en) 2018-07-26
CN108601790B (zh) 2026-01-27
EP3402486A4 (en) 2019-08-28
TW201726134A (zh) 2017-08-01
RU2742888C2 (ru) 2021-02-11

Similar Documents

Publication Publication Date Title
ZA201804513B (en) Method of treating c3 glomerulopathy
IL273959A (en) Methods and preparations for the treatment of rare diseases
IL273585A (en) Therapeutic methods related to HSP90 inhibitors
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2017010150A (es) Bacterias probioticas recombinantes.
ZA201903873B (en) Methods of treating cochlear synaptopathy
IL284797A (en) Addiction treatment methods
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
NZ722600A (en) Methods of treating mild brain injury
MX2017000306A (es) Metodos para tratar hipotension.
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EP3310377A4 (en) Method of treating crohn's disease
MX2019004804A (es) Tratamiento para el prurigo nodula.
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.